- Home
- Publications
- Publication Search
- Publication Details
Title
Bispecific antibodies and their applications
Authors
Keywords
Bispecific antibody, BiTE, Cancer, Formats, Catumaxomab, Diagnosis
Journal
Journal of Hematology & Oncology
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-12-21
DOI
10.1186/s13045-015-0227-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 989PDPHASE 1B STUDY OF MEHD7945A (MEHD) PLUS CISPLATIN/FLUOROURACIL (CIS/5FU) OR CARBOPLATIN/PACLITAXEL (CARBO/PAC) FOR 1ST-LINE TREATMENT OF RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (RMSCCHN)
- (2017) P.M. Clement et al. ANNALS OF ONCOLOGY
- 986ORANDOMIZED PHASE II STUDY OF MEHD7945A (MEHD) VS CETUXIMAB (CET) IN >= 2ND-LINE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD & NECK (RMSCCHN) PROGRESSIVE ON/AFTER PLATINUM-BASED CHEMOTHERAPY (PTCT)
- (2017) J. Fayette et al. ANNALS OF ONCOLOGY
- Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference
- (2016) Nikolett M. Biel et al. CANCER LETTERS
- The coming of age of engineered multivalent antibodies
- (2015) Natalia Nuñez-Prado et al. DRUG DISCOVERY TODAY
- Bispecific antibodies
- (2015) Roland E. Kontermann et al. DRUG DISCOVERY TODAY
- Duligotuzumab. Human anti-EGFR/anti-HER3 MAb, colorectal cancer therapy, head and neck cancer therapy
- (2015) P. Cole DRUGS OF THE FUTURE
- Bispecific antibodies, nanoparticles and cells: bringing the right cells to get the job done
- (2015) Junnan Tang et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Making a case for albumin – a highly promising drug-delivery system
- (2015) Angelica M Merlot et al. Future Medicinal Chemistry
- Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells
- (2015) Dongmei Fan et al. Journal of Hematology & Oncology
- AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
- (2015) Jingjing Wu et al. Journal of Hematology & Oncology
- AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells
- (2015) Dongmei Fan et al. Journal of Hematology & Oncology
- Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
- (2015) Thomas Köhnke et al. Journal of Hematology & Oncology
- Clinical overview of anti-CD19 BiTE® and ex vivo data from anti-CD33 BiTE® as examples for retargeting T cells in hematologic malignancies
- (2015) Gerhard Zugmaier et al. MOLECULAR IMMUNOLOGY
- Alternative molecular formats and therapeutic applications for bispecific antibodies
- (2015) Christoph Spiess et al. MOLECULAR IMMUNOLOGY
- Two-hit antibody tackles bacteria
- (2015) Katie Kingwell NATURE REVIEWS DRUG DISCOVERY
- Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG
- (2015) Nicolas Fischer et al. Nature Communications
- Abstract 669: Development of MGD007, a gpA33 x CD3 bi-specific DART for T-cell immunotherapy of metastatic colorectal cancer
- (2015) Paul A. Moore et al. CANCER RESEARCH
- New antibody approaches to lymphoma therapy
- (2014) Tejas Suresh et al. Journal of Hematology & Oncology
- A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies
- (2014) Caroline S Breton et al. Journal of Hematology & Oncology
- The therapeutic monoclonal antibody market
- (2014) Dawn M Ecker et al. mAbs
- Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface
- (2014) Steven M Lewis et al. NATURE BIOTECHNOLOGY
- Controlled Fab-arm exchange for the generation of stable bispecific IgG1
- (2014) Aran F Labrijn et al. Nature Protocols
- InterMune and Boehringer blaze trails for idiopathic pulmonary fibrosis drugs
- (2014) Katie Kingwell NATURE REVIEWS DRUG DISCOVERY
- Bispecific antibodies rise again
- (2014) Ken Garber NATURE REVIEWS DRUG DISCOVERY
- A multifunctional bispecific antibody protects against Pseudomonas aeruginosa
- (2014) A. DiGiandomenico et al. Science Translational Medicine
- Tumor-Antigen–Binding Bispecific Antibodies for Cancer Treatment
- (2014) Ulrich H. Weidle et al. SEMINARS IN ONCOLOGY
- A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML)
- (2014) Geoffrey Uy et al. Journal for ImmunoTherapy of Cancer
- Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
- (2013) Y. Kienast et al. CLINICAL CANCER RESEARCH
- Two-in-One antibodies with dual action Fabs
- (2013) Charles Eigenbrot et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Monoclonal antibody treatments for rheumatoid arthritis
- (2013) Lukas Bossaller et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors
- (2013) Alessandro Satta et al. Future Oncology
- Glycosylation analysis of an aggregated antibody produced by Chinese hamster ovary cells in bioreactor culture
- (2013) Masayoshi Onitsuka et al. JOURNAL OF BIOSCIENCE AND BIOENGINEERING
- Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity
- (2013) Whitney Shatz et al. mAbs
- MM-141, an IGF-IR- and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors
- (2013) J. B. Fitzgerald et al. MOLECULAR CANCER THERAPEUTICS
- How Cytokine Networks Fuel Inflammation: Interleukin-17 and a tale of two autoimmune diseases
- (2013) Dominique L. P. Baeten et al. NATURE MEDICINE
- Small nanobody drugs win big backing from pharma
- (2013) Sarah CP Williams NATURE MEDICINE
- How Cytokine Networks Fuel Inflammation: Toward a cytokine-based disease taxonomy
- (2013) Georg Schett et al. NATURE MEDICINE
- Targeting interleukin-6 in inflammatory autoimmune diseases and cancers
- (2013) Xin Yao et al. PHARMACOLOGY & THERAPEUTICS
- Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
- (2013) J. A. Couch et al. Science Translational Medicine
- Poster Sessions
- (2012) Eugen Dhimolea et al. mAbs
- World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA
- (2012) Eugen Dhimolea et al. mAbs
- Dual targeting strategies with bispecific antibodies
- (2012) Roland Kontermann mAbs
- Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
- (2012) C. F. McDonagh et al. MOLECULAR CANCER THERAPEUTICS
- From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines
- (2012) Jacques Banchereau et al. NATURE IMMUNOLOGY
- Blinatumomab: A historical perspective
- (2012) Dirk Nagorsen et al. PHARMACOLOGY & THERAPEUTICS
- DARTs take aim at BiTEs
- (2011) C. Rader BLOOD
- Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
- (2011) P. A. Moore et al. BLOOD
- Strategies for extended serum half-life of protein therapeutics
- (2011) Roland E Kontermann CURRENT OPINION IN BIOTECHNOLOGY
- Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
- (2011) W. Schaefer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bispecific digoxigenin-binding antibodies for targeted payload delivery
- (2011) S. Metz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid- Production in Vivo
- (2011) J. K. Atwal et al. Science Translational Medicine
- Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy
- (2010) Diane Seimetz et al. CANCER TREATMENT REVIEWS
- Bispecific antibodies for cancer therapy
- (2010) Patrick Chames et al. mAbs
- Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules
- (2010) Chengbin Wu et al. mAbs
- The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2
- (2009) M. Jager et al. CANCER RESEARCH
- A Novel Method of 18F Radiolabeling for PET
- (2009) W. J. McBride et al. JOURNAL OF NUCLEAR MEDICINE
- Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti‐CD20 × anti‐CD3), mediates efficient killing of B‐cell lymphoma cells even with very low CD20 expression levels
- (2008) Michael Stanglmaier et al. INTERNATIONAL JOURNAL OF CANCER
- The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics
- (2008) C.Simone Fishburn JOURNAL OF PHARMACEUTICAL SCIENCES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now